Matinas Biopharma Holdings Inc [MTNB] stock is trading at $0.93, up 10.88%. In order to assess the stock’s recent performance, you can check whether its short-term value is rising or falling. The MTNB shares have gain 5.84% over the last week, with a monthly amount glided 20.96%, and seem to be holding up well over a long-time horizon.
From an analyst’s perspective:
Matinas Biopharma Holdings Inc [AMEX: MTNB] stock has seen the most recent analyst activity on May 11, 2021, when Piper Sandler downgraded its rating to a Neutral. On January 27, 2020, Piper Sandler initiated with a Overweight rating and assigned a price target of $3 on the stock. SunTrust started tracking the stock assigning a Buy rating. SunTrust initiated its recommendation with a Buy. Aegis Capital started tracking with a Buy rating for this stock on January 09, 2020, and assigned it a price target of $3.50. In a note dated June 26, 2019, H.C. Wainwright initiated an Buy rating and provided a target price of $4 on this stock.
Matinas Biopharma Holdings Inc [MTNB] stock has fluctuated between $0.47 and $9.60 over the past year. Matinas Biopharma Holdings Inc [AMEX: MTNB] shares were valued at $0.93 at the most recent close of the market.
Analyzing the MTNB fundamentals
Gross Profit Margin for this corporation currently stands at -0.25% with Operating Profit Margin at -16.84%, Pretax Profit Margin comes in at -20.96%, and Net Profit Margin reading is -20.88%. To continue investigating profitability, this company’s Return on Assets is posted at -1.67, Equity is -1.65 and Total Capital is -1.66. An extended analysis of the company’s primary financial structure reveals a debt-to-equity ratio of0.43.
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance. The company’s stock is currently sitting at 0.7842 points at the first support level, and at 0.6371 for the second support level. However, for the 1st resistance point, the stock is sitting at 1.1342, and for the 2nd resistance point, it is at 1.3371.
Ratios To Look Out For
For context, Matinas Biopharma Holdings Inc’s Current Ratio is 3.35. In addition, the Quick Ratio stands at 3.35 and the Cash Ratio stands at 3.07.
